The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS ®)

Pain Medicine

Volumn 8, Issue 2, 2007, Pages 157-170

  Cicero, Theodore J ^a   Dart, Richard C ^b   Inciardi, James A ^c   Woody, George E ^d   Schnoll, Sidney ^e   Muñoz, Alvaro ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Rocky Mountain Poison Control Center   (United States)

^c UNIVERSITY OF DELAWARE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PURDUE PHARMA L P   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Opioid Analgesic Abuse; OxyContin ; Prescription Drug Abuse; Risk management Program

Indexed keywords

ALPRAZOLAM; ANALGESIC AGENT; BUPRENORPHINE; CARISOPRODOL; DIAZEPAM; FENTANYL; GUAIFENESIN; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; PENTAZOCINE; TRAMADOL;

ARTICLE; DRUG ABUSE; DRUG DEPENDENCE; DRUG MARKETING; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; GEOGRAPHY; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; LAW ENFORCEMENT; MEDICAL EXPERT; MEDICAL RESEARCH; OPIATE ADDICTION; PAIN; POISON CENTER; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; UNITED STATES; URBAN RURAL DIFFERENCE;

ANALGESICS, OPIOID; DATA COLLECTION; DELAYED-ACTION PREPARATIONS; HUMANS; HYDROCODONE; INDIANA; NATIONAL INSTITUTES OF HEALTH (U.S.); OPIOID-RELATED DISORDERS; OXYCODONE; POISON CONTROL CENTERS; POLICE; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION BEHAVIOR; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 33846978076     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2006.00259.x     Document Type: Article

References (32)

1. Inciardi JA, Goode JL. OxyContin and prescription drug diversion. Consumer Res 2003; 86: 17-21.
2. Joranson DE, Ryan KM, Gilson AM, et al. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283: 1710-4.
3. US Department of Justice Drug Enforcement Administration Diversion Control Program. Prescription Pain Medication: Frequently Asked Questions and Answers for Health Care Professionals and Law Enforcement Personnel. August 11, 2004. Available at: http://www.deadiversion.usdoj.gov/new.htm (accessed August 14, 2005).
4. Zacny J, Bigelow G, Compton P, et al. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend 2003; 69(3): 215-32.
5. Cicero TJ, Adams EH, Geller A, et al. A post-marketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7-22.
6. Cicero TJ, Inciardi JA. Diversion and abuse of methadone prescribed for pain management. JAMA 2005; 293: 297-8.
7. Cicero TJ, Inciardi JA, Adams EH, et al. Abuse and physical dependence on ultram, generic tramadol and ultracet in the United States: Results of a Post-Marketing Surveillance Program: 1994-2004. Pharmacoepidemiology and Drug Safety. 2005; 14: 851-9. Published online in Wiley Interscience (http://www.interscience.wiley.com). Digital Object Identifier (10.1002/pds.1113).
8. Government Accounting Office (GAO). Report to Congressional Requesters. Prescription Drugs: Oxycontin Abuse and Diversion and Efforts to Address the Problem. Dec. 2003; GAO-04-0110.
9. Substance Abuse and Mental Health Services Administration. 2003a. Results from the 2002 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NHSDA Series: H22, DHSS Publication No. SMA 03-3836; Rockville, MD.
10. Substance Abuse and Mental Health Services Administration. 2003b. Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002. Office of Applied Studies; NHSDA Series: D-24, DHSS Publication No. SMA 03-3780, Rockville, MD.
11. Faich GA. Adverse-drug reaction monitoring. N Engl J Med 1986; 314: 1589-92.
12. Fontanarosa PB, Drummond R, DeAngelis CD. Postmarketing surveillance-Lack of vigilance, lack of trust. J Am Med Assoc 2004; 292: 2647-50.
13. Piazza-Hepp TD, Kennedy DL. Reporting of adverse events to MedWatch. Am J Health Syst Pharm 1995; 2: 1436-9.
14. Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: A counterpoint. J Am Med Assoc 2004; 292: 2643-6.
15. U.S. Food and Drug Administration. Strengthening the science base for regulatory decisions. Jane E. Henney, 10th Annual PDA/FDA Joint Conference, Bethesda, Maryland. September 27, 1999; Available at: http://www.fda.gov/oc/speeches/pdafdaConference.html (accessed March 3, 2004).
16. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6: 662-72.
17. Inciardi JA, Chambers CD. Patterns of pentazocine abuse and addiction. NY State J Med 1971; 71: 1727-33.
18. National Institute on Drug Abuse, Community Epidemiology Work Group. Epidemiologic Trends in Drug Abuse Advance Report. National Institutes of Health, National Institute on Drug Abuse. Bethesda, MD: DHHS; 2002.
19. Senay EC. Clinical experience with T's & B's. Drug Alcohol Depend 1985; 14: 305-11.
20. Zacny J, Bigelow G, Compton P, et al. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend 2003; 69: 215-32.
21. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 56: 18-24.
22. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99.
23. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: A revisit. Pain Med 2004; 5(1): 59-65.
24. Gail MH, Benichou J. Encyclopedia of Epidemiologic Methods. New York, NY: John Wiley & Sons, Inc.; 2000: 433-7.
25. Agar MH. The Professional Stranger: An Informal Introduction to Ethnography. Orlando, FL: Academic Press; 1980.
26. Center for Substance Abuse Treatment, Methadone-Associated Mortality. Report of a National Assessment, May 8-9, 2003. SAMHSA, Publication Number 04-3904. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2004.
27. Cosman B, Feliciano WC, Wolff M. Pentazocine ulcers. Plast Reconstr Surg 1977; 59: 255-9.
28. Knisely JS, Campbell ED, Dawson KS, et al. Tramadol post-marketing surveillance in health care professionals. Drug Alcohol Depend 2002; 68: 15-22.
29. Breitbart W, Rosenfeld BD, Passik SD. The under treatment of pain in ambulatory AIDS patients. Pain 1996; 65: 239-249.
30. Ward SE, Goldberg N, Miller-McCauley V. Patient barriers to management of cancer pain. Pain 1993; 52: 319-324.
31. Ray WA, Stein MB. Reform of drug regulation-Beyond an independent drug-safety board. N Engl J Med 2006; 354: 194-201.
32. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302: 123.